JPMorgan analyst Anupam Rama downgraded iTeos Therapeutics (ITOS) to Neutral from Overweight.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics Ends Collaboration with GSK
- GSK, iTeos ending development program for belrestotug
- iTeos Therapeutics, GSK agree to terminate belrestotug development program
- iTeos Therapeutics initiates targeted review of strategic alternatives
- iTeos: GALAXIES Lung-201 did not meet criteria for meaninful improvements in PFS